Infectious Disease
circa 400 BCE, Ancient China (early Chinese medical texts describing epidemic jaundice); also referenced in Babylonian Talmud, circa 500 CE
Hepatitis B was a disease that puzzled physicians for centuries before its viral cause was identified in the twentieth century. Ancient healers observed jaundice and liver ailments that likely encompassed what would later be understood as hepatitis B, attributing these conditions to imbalances in bile and bodily humors. The long journey from ancient observation to viral discovery involved epidemiological investigations, wartime medical crises, and a Nobel Prize-winning breakthrough.
Historical Narrative
Among the earliest recorded observations of jaundice-like illness were descriptions found in ancient Babylonian and Chinese texts, where physicians noted a yellowing of the skin and eyes accompanied by profound weakness. The Babylonian Talmud contained references to an epidemic jaundice that rendered sufferers ritually unclean, suggesting the ancients had observed its communicable nature without understanding the mechanism. In ancient China, medical scholars writing around 400 BCE described what they called 'epidemic jaundice' and attributed it to environmental dampness and disruptions of the body's vital energy. Hippocrates and his followers in ancient Greece catalogued jaundice extensively, associating it with an excess of yellow bile in the liver, a framework that would dominate Western medical thinking for over a millennium. Galen elaborated on Hippocratic humoral theory in the second century CE, reinforcing the belief that the liver was the body's primary blood-producing organ and that jaundice arose from its dysfunction. Medieval Islamic physician Ibn Sina, known in the West as Avicenna, described epidemic jaundice in his landmark Canon of Medicine, noting that certain forms appeared to spread among populations, though he still interpreted the phenomenon through a humoral lens. European physicians during the Middle Ages and Renaissance continued to classify jaundice by its presumed humoral causes, distinguishing between obstructive and what they called 'catarrhal' forms, without any concept of infectious agents. A pivotal moment in the disease's history came during the eighteenth and nineteenth centuries, when military physicians began documenting outbreaks of jaundice among soldiers. The German physician Lurman conducted an important early epidemiological investigation in 1885, observing that workers who had received a smallpox vaccine derived from human lymph subsequently developed jaundice, while unvaccinated workers did not. This observation, published and largely overlooked at the time, was among the earliest documented evidence suggesting a transmissible agent in the blood could cause liver disease. During the First and Second World Wars, epidemic jaundice swept through military populations on an enormous scale, forcing military physicians to distinguish between what they termed 'infectious jaundice' and 'serum jaundice,' the latter associated with contaminated needles and biological products. Epidemiologists F.O. MacCallum and others in the 1940s provided clearer distinctions between what they labeled hepatitis A and hepatitis B, based on their different routes of transmission and incubation periods, though neither virus had yet been isolated. The decisive breakthrough came in 1965 when American physician and geneticist Baruch Blumberg was studying genetic variation in blood proteins among diverse human populations when he discovered an unusual antigen in the blood of an Australian Aboriginal patient. Blumberg initially called this the 'Australia antigen,' and through subsequent research conducted with virologist Alfred Prince and others, it became clear this antigen was associated with serum hepatitis. By the late 1960s and early 1970s, Blumberg's work had established that the Australia antigen was in fact a component of the hepatitis B virus itself, a discovery that earned him the Nobel Prize in Physiology or Medicine in 1976. His identification of the antigen also made possible the development of a diagnostic blood test in the early 1970s, fundamentally transforming how blood banks screened donated blood. Irving Millman collaborated with Blumberg to develop an early vaccine using purified Australia antigen from the blood of chronic carriers, a vaccine that underwent trials in the late 1970s and represented a landmark in the control of an infectious disease whose existence had been suspected for nearly a century.
Key Historical Figures
Historical narrative only — this page describes how Hepatitis B was understood historically. It is not medical advice and does not describe current diagnosis or treatment. Sourced from verified medical history references (NIH, Encyclopaedia Britannica, and standard medical history texts). See our medical disclaimer.